Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fierce Pharma Homepage
Biotech
Treasury COINS rules add biotech, spares China licensing deals
Despite the sweeping scope of the ban covering various drug modalities, biopharma business development teams can breathe a measured sigh of relief.
Angus Liu
Oct 22, 2026 11:36pm
AstraZeneca taps Oracle to improve recruitment for trials
Oct 20, 2026 2:36am
China looks to ban foreign acquisitions of key biotech platforms
Oct 16, 2026 10:38am
GSK to lay off 1,200 roles in Belgium under cost-saving program
Oct 14, 2026 6:37am
AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment
Sep 29, 2026 3:07am
Fierce Pharma
Lundbeck relocating US headquarters to Boston in innovation move
Sep 25, 2026 10:41am
More News
Overton backs vaccines, mifepristone in confirmation hearing
Sep 24, 2026 2:32pm
Fierce Pharma
Novo struggles to appease restless investors with new strategy
Sep 21, 2026 10:50am
Fierce Pharma
Novo CEO talks embracing change and staying bullish amid rebrand
Sep 17, 2026 8:45am
CEO O’Day tells Fierce how Gilead reached ‘critical mass’
Sep 16, 2026 8:00am
